Showing 26–50 of 200 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Ebenezer Tumban
…-converting enzyme 2 receptor on the cells. Thus, candidate vaccines targeting the spike protein are currently being developed to prevent against infections. Approximately 44 SARS-CoV-2 candidate vaccines are in clinical trials (phase I-III) and an additional 164 candidates are i…
Vasiliy Reshetnikov, Galina Shepelkova, Anna D. Rybakova, А. П. Трашков, Vladimir Yeremeev, et al.
mRNA vaccines turned out to be highly effective in combating the COVID-19 pandemic and other viral infections. Despite extensive study of mRNA vaccines in the last five years, the issue of safety of their use is still relevant. The study aimed to assess immunogenicity of two anti…
Arif Khan, Asad Khan, Irfan Khan, Muhammad Aamir Shehzad, Waqar Ali, et al.
…transformation technique to form a transgenic plant. Edible vaccines grip countless promise as a profitable, easily managing, can be store easily, unlikely or unable to fail and sociocultural gladly sustainable, particularly for the poor emerging nations. An edible vaccine takes …
Özgül Kısa
…here isan urgent need for the development of alternative TB vaccines. Recently, new TB vaccine development efforts havebeen advanced in different clinical studies. Most of these vaccines are live-attenuated or recombinant mycobacterium,live viral vector-based, and protein/adjuvan…
U. Yu. Sirodzhidinova, U. I. Rozikov, S. M. Saydaliev, J. M. Yusupdzhanova
Aim . To study morphological changes in the lymph nodes of experimental animals vaccinated with BCG vaccine in high and low mountains. Material and Methods . Guinea pigs from the vivarium of the Central Research Laboratory of the Avicenna Tajik State Medical University were used …
Александр Сидорчук, Александр Сидорчук
The article describes the historical stages of creating vaccines against two of the most dangerous diseases, which, after the discovery of the microbial theory, were devoted to the efforts of scientists ― rabies and tuberculosis. The lecture describes the main achievements of L. …
Engi Seif E. Shaker, Noha Nabil Doghim, Arwa M. Hassan, Samia S. Musafa, Mohamed M. Fawzy
BACKGROUND: Warts are common viral infection of the skin. Treating warts are still an ongoing challenge and no general agreement is reached, on the best treatment, despite different therapeutic approaches. Intralesional (IL) immunotherapy has recently been shown to be effective i…
А. M. Kostinov, М. П. Костинов
… provides data showing the nonspecific effect of preventive vaccines, such as pneumococcus, tuberculosis, and influenza, on the parameters of innate and adaptive immunity, which is reflected in a reduction of susceptibility not only to vaccine antigens, but also to other infectio…
Tatyana Zubkova
The aim of the study is to investigate safety, reactogenicity and immunogenicity of the TB/Flu-05E single-dose intranasal vaccine for the prevention of Tuberculosis infection in BCG-vaccinated Volunteers aged 18-50 years. Study include 51 participants in two cohorts. At the firs…
Helen McShane, Alison Elliot
Mycobacterium tuberculosis (M. tb) is a pathogen with worldwide distribution which infects humans causing tuberculosis (TB), a transmissible disease resulting in very high mortality and morbidity; development of an effective vaccine is a global health priority. Over a billion pe…
Manuja Gunasena, Rajni Kant Shukla, Naiquan Yao, Oscar Rosas Mejia, Michael D. Powell, et al.
Abstract The vaccine Mycobacterium bovis Bacillus Calmette–Guérin (BCG) elicits an immune response that is protective against certain forms of tuberculosis (TB); however, because BCG efficacy is limited it is important to identify alternative TB vaccine candidates. Recently, the …
GSK Clinical Trials
The purpose of this study is to assess the safety and immunogenicity of two doses of the TB vaccine administered according to a 0, 1 month schedule. In, addition, blood samples collected at different time points after vaccination will be analysed to see when exactly genes are act…
BioNTech Responsible Person
…ill evaluate four dose levels of the BNT164 investigational vaccines (BNT164a1 and BNT164b1) to select a safe and tolerable dose in a three-dose schedule. Enrollment for BNT164a1 and BNT164b1 will be conducted independently, and in parallel. The trial will enroll participants di…
Michele Tameris, M.B.Ch.B.
The purpose of this study is to determine the safety, tolerability, and immunogenicity in BCG-vaccinated healthy adult subjects of an investigational vaccine being developed for the prevention of pulmonary tuberculosis.
ФГБОУ ВО «Астраханский государственный медицинский университет» Минздрава России, Л. Г. Тарасова, E.N. Streltzova
BCG is a unique vaccine. It was created and successfully used for specific prevention of tuberculosis. Reactivation of the BCG scar is a transient condition that occurs against the background of various diseases, capable of resolving itself, does not involve surgical intervention…
Yang Wang, Fei Ge, Junhai Wang, Hanglin Li, Boyang Zheng, et al.
…bstacle to the development of safe and effective killed RSV vaccines.
Daifulah Al-Zahrani
Tuberculosis (TB) is considered by WHO as a worldwide wellbeing crisis in 1993. In 2011 33% of the total populace was believed to be contaminated with TB and 8.7 million instances of dynamic TB every year. BCG antibody is one of the successful control measures to forestall TB. It…
Gönül Aslan, Deniz Alkaya
ÖzTüberküloz (TB) Mycobacterium tuberculosis kompleksi'nin etken olduğu ciddi etkileri nedeniyle insanlık tarihi boyunca toplumları derinden etkileyen bulaşıcı bir hastalıktır.TB'den korunmada tarihi bir öneme sahip olan Bacille Calmette-Guérin (BCG) aşısı 100 yıllık geçmişi ile
World Health Organization = Organisation mondiale de la Santé
A. М. Krychkovska, N. L. Zayarnyuk, О. І. Lopatynska, L. D. Bolibruh, В. П. Новіков
International scientific and practical conference «New trends and unresolved issues of preventive and clinical medicine» : Conference proceedings, September 25–26, 2020. Lublin : Izdevnieciba «Baltija Publishing», 2020. 428 pages.
Darmanger, A. M., Nekzad, S. M., Kuis, M., ten Dam, H. G.
World Health Organization
World Health Organization
Obayashi, Yoji, Sawada, Tetsuji, Kuchiki, Gorosaku, Cho, Chujo, Kawasaki, Jiro, et al.